A membrane-associated MHC-I inhibitory axis for cancer immune evasion
Xufeng Chen,Qiao Lu,Hua Zhou,Jia Liu,Bettina Nadorp,Audrey Lasry,Zhengxi Sun,Baoling Lai,Gergely Rona,Jiangyan Zhang,Michael Cammer,Kun Wang,Wafa Al-Santli,Zoe Ciantra,Qianjin Guo,Jia You,Debrup Sengupta,Ahmad Boukhris,Hongbing Zhang,Cheng Liu,Peter Cresswell,Patricia L M Dahia,Michele Pagano,Iannis Aifantis,Jun Wang
DOI: https://doi.org/10.1016/j.cell.2023.07.016
IF: 64.5
2023-08-31
Cell
Abstract:Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of resistance is immune evasion of T cell immunity involving aberrant major histocompatibility complex class I (MHC-I) antigen presentation (AP). To map such mechanisms of resistance, we identified key MHC-I regulators using specific peptide-MHC-I-guided CRISPR-Cas9 screens in AML. The top-ranked negative regulators were surface protein sushi domain containing 6 (SUSD6), transmembrane protein 127 (TMEM127), and the E3 ubiquitin ligase WWP2. SUSD6 is abundantly expressed in AML and multiple solid cancers, and its ablation enhanced MHC-I AP and reduced tumor growth in a CD8+ T cell-dependent manner. Mechanistically, SUSD6 forms a trimolecular complex with TMEM127 and MHC-I, which recruits WWP2 for MHC-I ubiquitination and lysosomal degradation. Together with the SUSD6/TMEM127/WWP2 gene signature, which negatively correlates with cancer survival, our findings define a membrane-associated MHC-I inhibitory axis as a potential therapeutic target for both leukemia and solid cancers.